Toray Industries, Inc.

Kyoto University

National Cancer Center

Aiko Takayama

Hiroko Sudo

Atsuko Miyano

Taiga Arai

Giman Jung

Yoshinori Tanaka

Satoko Kanamori

Michimoto Kobayashi

Hiroshi Okabe

Tesshi Yamada

Kazufumi Honda

Yoshiharu Sakai

Mitsuaki Sanada

Yoshiyuki Sasajima

The present invention provides a novel pharmaceutical composition for treating and/or preventing cancer comprising, as an active ingredient, a polynucleotide derived from various miRNAs associated with cancer, a combination drug of the pharmaceutical composition and another antitumor agent, and a method for treating or preventing cancer in a subject having the cancer using the pharmaceutical composition or the combination drug. The present invention relates to a pharmaceutical composition for treating and/or preventing cancer comprising, as an active ingredient, a polynucleotide comprising the nucleotide sequence as set forth in SEQ ID NO: 1, or a nucleotide sequence comprising a substitution of one nucleotide in the nucleotide sequence as set forth in SEQ ID NO: 1 (wherein when at least a part of the polynucleotide is DNA, uracil in a region corresponding to the DNA in the nucleotide sequence is replaced with thymine).

Pharmaceutical composition for treating and/or preventing cancer

The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.

Method and kit for the detection of biliary tract cancer

The present application provides a pharmaceutical composition for treating and/or preventing a cancer comprising, as an active ingredient, a polynucleotide derived from miRNA associated with the cancer, a combination drug of the pharmaceutical composition and another antitumor agent, and a method for treating or preventing a cancer in a subject having the cancer using the pharmaceutical composition or the combination drug.

It is an object of the present invention to specify miRNA associated with the treatment and/or prevention of various cancer species, from among various miRNAs associated with cancer, and to provide a novel pharmaceutical composition for treating and/or preventing cancer which targets the specified miRNA. According to the present invention, provided are a pharmaceutical composition for treating and/or preventing cancer comprising, as an active ingredient, an antisense polynucleotide shown as hsa-miR4454, a combination drug comprising the aforementioned pharmaceutical composition and another antitumor agent, and a method for treating and/or preventing cancer, using the above-described pharmaceutical composition or combination drug.

The present invention provides a novel pharmaceutical composition for treating and/or preventing a cancer comprising, as an active ingredient, a polynucleotide derived from various miRNAs associated with cancer, a combination drug of the pharmaceutical composition and another antitumor agent, and a method for treating or preventing a cancer in a subject having the cancer using the pharmaceutical composition or the combination drug. The present invention relates to a pharmaceutical composition for treating and/or preventing a cancer comprising, as an active ingredient, a polynucleotide comprising the nucleotide sequence as set forth in SEQ ID NO: 1 or 2 (wherein when at least a part of the polynucleotide is DNA, uracil in a region corresponding to the DNA in the nucleotide sequence is replaced with thymine).

An object of the present invention is to detect a human CXCL1 protein with high sensitivity. An immunoassay method is provided for a human CXCL1 protein, by which human CXCL1 or a fragment thereof in a sample is measured using two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof, wherein:

Immunoassay method for human CXCL1 protein

An object of the present invention is to realize an antibody or a fragment thereof specifically recognizing a cofilin 1 protein, and a method for detecting and testing gastrointestinal cancer with high detection performance, which comprises performing immunoassay of the cofilin 1 protein using the antibody or a fragment thereof. An immunoassay of cofilin 1 protein is characterized by measuring cofilin 1 or a fragment thereof in a sample using 2 or more types of anti-cofilin 1 monoclonal antibody or fragments thereof specifically recognizing different peptide regions in the amino acid sequence constituting the cofilin 1 protein.

Growing community of inventors

Kamakura, Japan

Aiko Takayama